Weekly Roundup for June 21, 2024: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Every week we review the most recent publications in women’s mental health.
A New Drug Application was submitted to the FDA for a novel, nonhormonal dual neurokinin-1 and neurokinin-3 receptor antagonist for the treatment of menopause-related vasomotor symptoms.
Those with depression are at greater risk of experiencing IPV and experiencing IPV is associated with higher levels of depressive symptoms.
This meta-analysis suggests that mind-body therapies are an effective treatment for women victims of violence.
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
Longer-term studies supporting the safety and efficacy of TMS during pregnancy are needed.
There is a wide range of barriers across multiple levels--individual, healthcare professional, interpersonal, organizational, political, and societal.
There is little published data on the use of St. John's wort during breastfeeding and because we lack data, we would typically recommend using a conventional antidepressant, such as an SSRI or SNRI.Â
In women with ADHD, about 60% of women with ADHD elect to discontinue ADHD medications around the time of conception.
This review and meta-analysis reviews the effectiveness of cognitive behavioral therapy and mindfulness interventions for depression, anxiety, and cognitive functioning in women undergoing menopausal transition. Â